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Context: The DICER1 syndrome is a multiple neoplasia disorder caused by germline
mutations in theDICER1 gene. In DICER1 patients, aggressive congenital pituitary tumors
lead to neonatal Cushing’s disease (CD). The role of DICER1 in other corticotropinomas,
however, remains unknown.
Objective: To perform a comprehensive screening for DICER1 variants in a large cohort
of CD patients, and to analyze their possible contribution to the phenotype.
Design, setting, patients, and interventions: We included 192CD cases: ten
young-onset (age <30 years at diagnosis) patients were studied using a next generation
sequencing panel, and 182 patients (170 pediatric and 12 adults) were screened
via whole-exome sequencing. In seven cases, tumor samples were analyzed by
Sanger sequencing.
Results: Rare germline DICER1 variants were found in seven pediatric patients with
no other known disease-associated germline defects or somatic DICER1 second hits.
By immunohistochemistry, DICER1 showed nuclear localization in 5/6 patients. Variant
transmission from one of the parents was confirmed in 5/7 cases. One patient had a
multinodular goiter; another had a family history of melanoma; no other patients had a
history of neoplasms.
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Conclusions: Our findings suggest that DICER1 gene variants may contribute to
the pathogenesis of non-syndromic corticotropinomas. Clarifying whether DICER1
loss-of-function is disease-causative or a mere disease-modifier in this setting,
requires further studies.
Clinical trial registration: ClinicalTrials.gov: NCT00001595.
Keywords: pituitary neuroendocrine tumor, Cushing’s disease, DICER1, disease-modifying gene, corticotropinoma
INTRODUCTION
Multiple molecular mechanisms causing pituitary
neuroendocrine tumors (PitNETs) have been identified, but
the genetic defects underlying such neoplasms remain unknown
for the majority of the sporadic cases. The most common somatic
genetic defects in somatotropinomas and corticotropinomas are
activating somatic mutations in the GNAS (guanine nucleotide-
activating alpha-subunit) and USP8 (ubiquitin-specific protease
8) genes, respectively. On the other hand, 5–8% of PitNETs
arise in a familial setting, either isolated (familial isolated
pituitary adenoma) or as part of a syndrome affecting other
organs, such as multiple endocrine neoplasia type 1 and type 4,
McCune-Albright syndrome and Carney complex, and more
rarely, within the DICER1 and succinate dehydrogenase-related
syndromes (1).
The DICER1 gene (14q32.13) encodes a ubiquitously
expressed enzyme containing two endoribonuclease III domains
(RNase IIIa and IIIb), required for the cleavage of precursor
molecules into mature microRNAs (2–4). Germline or mosaic
loss-of-function (LOF) DICER1 mutations predispose to
DICER1 syndrome or pleuropulmonary blastoma (PPB)
familial tumor and dysplasia syndrome, an autosomal dominant
condition causing PPB and multiple other tumors (5, 6).
Pituitary blastoma (PitB) is a recently described component of
this syndrome, causing severe neonatal Cushing’s disease (CD)
due to a malignant congenital pituitary tumor, with or without
other associated tumors (7–9). Deleterious germline and somatic
DICER1 variants have also been reported in various sporadically
occurring neoplasms (10–12).
The clinical presentation of the DICER1 syndrome is quite
variable, and PitB displays low penetrance (8). Growing evidence
has demonstrated the role of miRNAs and long non-coding
RNAs in pituitary tumorigenesis (13, 14). Nevertheless, the
specific role of DICER1 in pituitary function and tumorigenesis
remains unknown. Therefore, we have performed a thorough
screening for DICER1 variants in CD patients using targeted
next generation sequencing (NGS) and whole-exome sequencing
(WES). We describe, for the first time, rare variants in
the DICER1 gene in seven patients presenting with isolated
corticotropinomas and CD arising during childhood.
SUBJECTS AND METHODS
Patients and Samples
We studied 170 pediatric (≤18 years at disease onset) and 12
adult CD patients who are part of a large cohort recruited at
the National Institutes of Health (NIH) Clinical Research Center
between 1997 and 2018 under the research protocol 97-CH-0076
(ClinicalTrials.gov: NCT00001595). The Eunice Kennedy Shriver
National Institute of Child Health and Human Development
Institutional Review Board approved the study, and informed
assent/consent was obtained from all the patients and their
parents or guardians. Clinical data were obtained directly from
the patients and/or from their medical records. For the patients
and their parents, if available, DNA was extracted either from
peripheral blood samples using the Maxwell 16 Blood DNA
Purification Kit in a Maxwell 16 Instrument (Promega AS1015
and AS3050) or from saliva using the Oragene-Dx collection
kit and the PrepIT-L2P DNA extraction kit (DNA Genotek
OGD-500 and PT-L2P-45), according to the manufacturer’s
protocols. Additional studies in this cohort have been reported
elsewhere (15–22).
We also studied ten young patients (age <30 years at
diagnosis) with diagnosed familial or sporadic CD; these cases
are part of a multicenter study performed at the Biocruces Bizkaia
Health Research Institute and the Department of Endocrinology
and Pediatric Endocrinology at the Cruces University Hospital
(Barakaldo, Spain). Clinical data were provided by the clinicians
responsible for these patients and written informed consent
was obtained from all participants or their parents. The study
was approved by the local Ethics committees. Extraction and
purification of DNA from peripheral blood leukocytes was
performed using the MagPurix Blood DNA Extraction Kit 200,
according to themanufacturer’s instructions (Zinexts Life Science
Corp., Taiwan).
When possible, unstained tumor slides were obtained from
the corresponding departments of Anatomical Pathology. After
manual delimitation of the tumor area, DNA was extracted
from unstained sections using the Pinpoint Slide DNA Isolation
System (Zymo Research D3001).
Written, informed consent was obtained from the individuals
and/or minors’ legal guardian for the publication of any
potentially identifiable images or data included in this article.
Design of a Targeted Gene Panel and
Screening via Next-Generation Sequencing
A targeted panel for PitNETs was designed to include nine
genes (AIP, CDKN1B,DICER1,GNAS,MEN1, PRKAR1A, SDHB,
SDHC, and SDHD) associated with human pituitary tumors
in online databases, including PubMed (https://www.ncbi.nlm.
nih.gov/pubmed/), Human Gene Mutation Database (HGMD,
https://portal.biobase-international.com) and Online Mendelian
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Inheritance in Man (https://www.ncbi.nlm.nih.gov/omim). The
design of the panel was performed by Ion AmpliSeqTM Designer
(Thermo Fisher Scientific, USA) and oligonucleotides against
exons, flanking intronic and untranslated (UTR) regions were
included. Library preparation was done using the Ion Ampliseq
Library Kit v2.0 (Thermo Fisher Scientific) according to
manufacturer’s instructions. Samples were then sequenced using
the Personal Genome Machine system with an Ion 316TM
Chip (Thermo Fisher Scientific). Base calling, read filtering,
alignment to the reference human genome GRCh37/hg19, and
variant calling were done using Ion Torrent Suites (Thermo
Fisher Scientific). Further QC analysis, coverage analysis,
and variant filtering were completed with the Ion Reporter
Software (Thermo Fisher Scientific). Coverage depth and read
quality were also evaluated with the Integrative Genomics
Viewer (broadinstitute.org).
Germline DNA samples from the 182 patients studied at
NIH were submitted for WES at the University of Minnesota
Genomics Center (UMGC, 91 patients) or Novogene (91
patients) and analyzed at UMGC. Targeted capture libraries
were generated using the Agilent QXT v5 + UTRs (UMGC)
or SureSelect Human All Exon v6 (Novogene) kits. Samples
were sequenced on an Illumina HiSeq 2000 platform producing
100 base pair paired-end reads (UMGC) or on an Illumina
HiSeq 2500 platform producing 150 bp paired-end reads
(Novogene), while tumor samples were sequenced on a
HiSeq 2500 platform producing 1,265 bp paired-end reads.
WES results for all samples were analyzed together. FASTQ
files were processed using a Genome Analysis Toolkit
(GATK) v3.7 based pipeline, including BWA-MEM v0.7.17
for alternate contig aware alignment to the hg38 reference
genome (GRCh38_full_analysis_set_plus_decoy_hla.fa),
Picard Tools v2.6.0 to mark duplicates (picard, retrieved
from http://broadinstitute.github.io/picard/), and GATK for
indel realignment, base quality recalibration, genotyping
(HaplotypeCaller), variant quality score recalibration, and
to split multiallelic sites (23, 24). ANNOVAR was used to
determine the effect of coding variants using both the RefSeq
and UCSC gene sets, including putative amino acid changes,
distance to intron-exon boundary, the creation or removal of
a stop-codon, and location within known non-coding RNAs
(25). Non-synonymous variants were annotated based on their
computationally predicted deleteriousness using information
from dbNSFP. All variants were annotated for their presence
and frequency in multiple variant collections (e.g., dbSNP,
1,000 Genomes, and internal WES datasets totaling over 10,000
samples). All the results were filtered to include only variants
with a Phred-like score ≥30. The median number of on-target
reads generated per sample was 451 million, resulting in a
median target coverage of 60X (89% of targets covered at





UTR) and had a median
percent covered at 20X of 0.0%. Of the 26 coding exons in
DICER1, 20 had a median percent covered at 20X of 95% or
greater. Exons 7 (73.1%), 8 (41.9%), 9 (20.2%), 10 (90.0%), 28
(46.7%), and 29 (80.6%) each had a median percent covered at
20X of <95%.
In silico Analyses and Variant Classification
The impact of non-synonymous variants on protein structure
and function was assessed in silico using Mutation Taster (http://
www.mutationtaster.org/), MutPred (http://mutpred.mutdb.
org/), Polyphen 2 (http://genetics.bwh.harvard.edu/pph2/),
PROVEAN (Protein Variation Effect Analyzer) (http://provean.
jcvi.org/index.php), SIFT (Sorting Intolerant from Tolerant,
http://sift.jcvi.org/), SNPs and Go (http://snps.biofold.org/snps-
and-go/snps-and-go.html), and VarSome (https://varsome.
com). Variants were classified following the standards and
guidelines from the American College of Medical Genetics and
Genomics (26). We focused our study on coding variants with a
minor allele frequency (MAF) <1% in gnomAD (http://gnomad.
broadinstitute.org).
Sanger Sequencing
Variants of interest were confirmed by bidirectional direct
sequencing using the BigDye Terminator 3.1 Cycle Sequencing
Kit (Thermo Fisher Scientific 4337456) in a 3500xL Genetic
Analyzer (Applied Biosystems, primer sequences, and conditions
are available from the authors, on request). All variants
were annotated according to the GenBank reference sequences
NM_030621.4 and NP_085124.2. When available, DNA samples
from the patients’ parents were screened likewise. Since all the
selected variants were heterozygous at the germline level, loss
of heterozygosity (LOH) in the tumors was also investigated. In
addition, the sequence encoding the RNAse IIIb domain (amino
acids 1666–1824) of DICER1 was sequenced from tumor DNA
samples. Previously reported clinical associations were searched
in the databases ClinVar (https://www.ncbi.nlm.nih.gov/clinvar),
catalog of Somatic Mutations in Cancer (COSMIC, https://
cancer.sanger.ac.uk/cosmic), and HGMD. In selected cases, the
primers 5′-CTTCCACCCCTCCAACTCAT-3′ and 5′-TGGAG
TTACTGTTGGCTTCCT-3′ were used to amplify and sequence
a region of 146 bp covering the USP8 mutational hotspot in
tumor DNA.
Immunohistochemistry
Immunohistochemical staining for DICER1 was performed
using 1:200 polyclonal rabbit anti-DICER1 primary antibody
(Sigma-Aldrich HPA000694), and amplification with 1:1,000
Biotin-SP AffiniPure Goat Anti-rabbit IgG and 1:500 peroxidase
streptavidin (Jackson ImmunoResearch Laboratories 111-065-
144 and 016-030-084, respectively). Samples were developed
using ImmPACT DAB peroxidase (HRP) substrate (Vector SK-
4105). The rest of the protocol has been detailed elsewhere (19).
Images were acquired using a Keyence BZ-X710 microscope and
processed with the BZ-X Analyzer software (Keyence).
Statistical Analyses
The Prism v8.2.1 software (GraphPad Software) was used for
all statistical analyses. Parametric data are presented as mean
± standard deviation and non-parametric data are presented as
median and interquartile range. Gene variant frequencies in the
study population were compared with the frequencies reported in
public databases using the chi-squared or the Fisher’s exact test,
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as appropriate. Results were considered statistically significant
when P < 0.05.
RESULTS
Study Population
The Biocruces Bizkaia Health Research Institute included 10
probands (60% females), with mean age at diagnosis of 17.9
(7.5–29.0) years and median tumor size of 17.4 (9–20) mm. The
NICHD cohort included 182 patients, 56.6% (n = 103) females
and 43.4% (n = 79) males. The median age at first symptoms
and diagnosis were 10 (8–13) and 12.8 (10.5–15.5) years among
the pediatric patients, while adult patients had a mean age of
38.8 ± 9.5 at first symptoms and 42 ± 12.6 at diagnosis. The
median maximum tumor diameter was 5.8 (4–8) mm; 84.1% (n
= 153) of patients had a microadenoma, 12.1% (n = 22) had
a macroadenoma, 2.7% (n = 5) had multiple adenomas, and
two patients had no tumor identifiable by histopathology (CD
was proven in these cases by means of bilateral inferior petrosal
sinus sampling, BIPSS, and resolution of hypercortisolemia after
surgery). Fifteen patients had familial presentation and the rest
were apparently sporadic. Except for somatic genomic instability
in Case 2 (detailed below), none of the patients with DICER1
variants reported here have other known germline PitNET-
associated genetic defects.
Patients With DICER1 Gene Variants of
Interest
We found seven germline heterozygous missense DICER1 gene
variants of interest each in an unrelated patient presenting
with non-syndromic, apparently sporadic CD during childhood
(one patient from the Biocruces Bizkaia cohort and six
from the NICHD cohort). The patients’ clinical, biochemical,
and histopathological data are summarized in Table 1, and
representativeMRI images are presented in Figure 1. The genetic
characterization and previous reports of the variants are detailed
in Table 2 and Figure 2. In addition to these infrequent variants,
we found that other, more common DICER1 variants, were
overrepresented in our cohort, compared with the general
population, as presented in Supplemental Table 1.
Case 1
After a 1-year history of weight gain, reduced growth velocity,
acanthosis nigricans, fatigue, and mood disturbances, this
boy was diagnosed with CD at age 7.8 years. He had an
elevated midnight serum cortisol, a positive CRH stimulation
test (CRHST), and a possible pituitary microadenoma by
magnetic resonance imaging (MRI); CD was confirmed by
BIPSS. Remission was only achieved after two transsphenoidal
surgeries and, in addition to a histologically confirmed PitNET,
an intermediate lobe cyst was also resected. His family history
is relevant for the diagnosis of skin melanoma in his mother,
maternal grandfather, and a maternal great-uncle. The variant
c.20A>G, p.Q7R (previously reported as a likely benign change
in DICER1 syndrome patients and as a somatic change in a case
of breast cancer) was detected in the patient, as well as in his
mother and maternal grandfather.
Case 2
This female patient was diagnosed with CD at age 8.6 years,
after having developed excessive weight gain, reduced growth
velocity, hirsutism, and mood disturbances over the previous 1.5
years. She had elevated urinary free cortisol (UFC) and midnight
serum cortisol, and her pituitary MRI revealed a macroadenoma.
A corticotropinoma with invasion of the medial wall of the
right cavernous sinus was resected, and the patient achieved
remission. The variant identified in this case (c.184G>A, p.V62I),
is extremely rare in the general population. It has been reported
before as a germline variant probably associated with two
cases of rhabdomyosarcoma, as a probable variant of uncertain
significance (VUS) in DICER1 syndrome, and as a somatic
change in colon adenocarcinoma.
Case 3
At age 9 years, this male patient developed excessive weight
gain, headaches, tinea corporis, red striae, facial plethora, and
fatigability. During his clinical evaluation, a dorsocervical fat
pad, hypertension, and reduced growth velocity were also
noted. He was diagnosed with CD at age 12.8 years, having
elevated UFC and midnight serum cortisol, as well as a
positive overnight low-dose dexamethasone suppression test
(LDDST) and an MRI showing a microadenoma. The patient
developed hypocortisolism after transsphenoidal surgery, and a
corticotropinoma was histologically confirmed. He carried the
variant c.485G>A, p.G162D, which has been reported before in
patients with DICER1 syndrome as a benign or likely benign
variant, and as a somatic change in a patient with Wilms tumor.
Case 4
At age 9 years, this female patient developed visual
impairment, striae, proximal myopathy and clinical features
of hyperandrogenism. Blood tests detected increased UFC and
IGF-1, and the patient was diagnosed with CD. MRI showed
a pituitary macroadenoma and transsphenoidal surgery was
performed. Tissue immunohistochemistry was positive for
ACTH. After surgery, the patient required treatment with
ketoconazole and cabergoline, and 1 year later, a second surgery
was performed due to persistent cortisol hypersecretion. At
age 11 years, the patient presented with a second recurrence,
which was successfully treated by radiotherapy. IGF-1 levels were
within the normal range after the second surgery (127 ng/ml).
At age 13 years, she presented with panhypopituitarism, obesity,
and insulin resistance. The variant c.1381A>G, p.I461V in exon
11 of DICER1 was found in the patient and in her apparently
healthy father.
Case 5
Around age 13 years, this female patient developed excessive
weight gain with central fat distribution, reduced growth
velocity, acne, acanthosis nigricans, facial plethora, striae,
dorsocervical fat pad, hypertension, secondary amenorrhea, and
mood disturbances. She had elevated UFC and midnight serum
cortisol, and anMRI showing amicroadenoma; a diagnosis of CD
was established at age 16.1 years. During her first transsphenoidal
surgery, invasion of the wall of the cavernous sinus was























































7.8 Weight gain (weight + 6.9 SDS),
growth rate deceleration (height
+ 0.8 SDS), acanthosis
nigricans, fatigue, mood
disturbances
UFC: 13.6 µg/24 h (6.8
× ULN); midnight serum
cortisol: 10.2 µg/dl; CRH
stimulation test: 151%
increase in cortisol and
512% increase in ACTH;
BIPSS: maximum
central-peripheral ratio of
15.5, left-right ratio of
11.6
PitNET (no IHC) Microadenoma (7
× 6 × 3mm)










8.5 Weight gain (weight + 2.8 SDS),
growth rate deceleration (height
−1 SDS), hirsutism, and mood
disturbances
UFC: 191.4 µg/24 h (9.6
× ULN); midnight serum
cortisol: 17.5 µg/dl;
CRHST: 175.6% increase
in cortisol and 500.7%
increase in ACTH
Corticotropinoma Macroadenoma
(12 × 18mm) with
invasion to the
medial wall of the
right cavernous
sinus

















12.8 Weight gain (weight + 3.2 SDS),
headaches, tinea corporis, striae,
facial plethora, fatigue,
dorsocervical fat pad,
hypertension, and growth rate
deceleration (height −1.9 SDS)
UFC: 209 µg/24 h (5.6 ×
ULN); midnight serum
cortisol: 14.9 µg/dl;
08:00 a.m. serum cortisol
post-overnight LDDST: 2
µg/dl; CRHST: 135%
increase in cortisol and
727% increase in ACTH
Corticotropinoma Microadenoma (4















9 Visual impairment, striae,
proximal myopathy,
hyperandrogenism and central
obesity (BMI +3.4 SD)
UFC: 914.1 µg/24 h (6.8
× ULN); IGF-1: 718 ng/ml
Corticotropinoma
(negative IHC for
prolactin, GH, FSH, LH,
and TSH)
Macroadenoma


















16.3 CD-related: weight gain (weight










UFC: 87.2 µg/24 h (1.6
× ULN); midnight serum
cortisol: 4.7 µg/dl;
CRHST: 145% increase



























































































































10.8 Weight gain (weight 4.5 SDS),
growth rate deceleration (height
−0.6 SDS), facial plethora,
fatigue and mood disturbances,
dorsocervical fat pad,
supraclavicular fat deposition,
proximal muscle weakness, and
hypertension
UFC: 389 µg/24 h (10.5




<100); 08:00 a.m. serum
cortisol post-overnight
LDDST: 15.4 µg/dl;
CRHST: increase 61% in


















8.4 Headache, dizziness, weight gain
(weight 4.4 SDS) and growth rate
deceleration (height −0.4 SDS)





9.7 µg/dl; CRHST: 90%
increase in cortisol and
306% increase in ACTH;
BIPSS: maximum
central-peripheral ration


















BIPSS, bilateral inferior petrosal sinus sampling; CRHST, CRH-stimulation test; IHC, immunohistochemistry; LDDST, low-dose dexamethasone suppression test; LOH, loss of heterozygosity; n/a, not available; PitNET, pituitary
neuroendocrine tumor; SDS, standard deviation score; TSS, transsphenoidal surgery; UFC: urinary free cortisol; ULN, upper limit of normal; wt, wild type.
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FIGURE 1 | Representative preoperative MRI images of the PitNETs diagnosed in Cases 1–4, 6, and 7. Image for Case 5 was obtained after her first surgery
(preoperative image not available). Blue arrows: tumors, yellow arrows: medial lobe cyst.
documented and histopathological examination confirmed a
Crooke’s cell corticotropinoma. A second transsphenoidal
surgery resulted in remission; unfortunately, she presented
with a new recurrence one year later and radiotherapy was
then administered, followed by treatment with ketoconazole.
The patient has a personal history of nighttime hypoxia,
polycythemia, and multinodular goiter, but no family history
of neoplasms. She carried the DICER1 variant c.3227G>A,
p.S1076N, reported in ClinVar as a VUS for DICER1 syndrome,
which she inherited from her apparently healthy father.
Case 6
At age 9 years, this previously healthy boy developed
excessive weight gain with central fat distribution, growth
rate deceleration, facial plethora, fatigability, and mood
disturbances. During clinical examination, dorsocervical fat
pad, supraclavicular fat deposition, proximal muscle weakness,
and hypertension were also found. He was diagnosed with
CD at age 10.8 years. Relevant findings during his diagnostic
workup included combined dyslipidemia, as well as elevated
UFC, unsuppressed midnight serum and salivary cortisol,
positive LDDST, and CRHST and a pituitary microadenoma
by MRI. Remission was achieved after transsphenoidal surgery
and histopathological examination revealed a Crooke’s cell
corticotropinoma. The variant c.3422C>T, p.S1141F, detected
in the patient and his mother, has been classified as a VUS in
patients with DICER1 syndrome and has also been reported as a
somatic change in one case of malignant melanoma.
Case 7
This female patient had a history of episodes of headache and
dizziness starting at age 3 years. At age 5 she also developed,
excessive weight gain with central fat distribution and growth
rate deceleration. At age 8.4 the patient was diagnosed with
CD, following biochemical tests showing elevated UFC and
midnight serum cortisol and an MRI demonstrating a pituitary
microadenoma. A corticotropinoma with invasion of the medial
wall of the left cavernous sinus was resected, leading to
disease remission. The patient carried the variant c.4891T>C,
p.S1631A; this change was inherited from her father, who
is affected with hypertension and hyperuricemia, but has no
history of neoplasms. This variant has been reported as a likely





At the somatic level, none of the cases presented LOH for
the DICER1 germline variants of interest, and no additional













































dbSNP ID MAF in gnomAD (v2.1.1) In silico prediction Pathogenic associations













rs117358479 0.1693 0.1720 0.1696 P n/a B N D N Likely benign ClinVar RCV000493327.2:
hereditary cancer-predisposing






PPB, likely benign. COSMIC: found





rs746671039 0.0008 n/a 0.0008 DC Altered metal
binding
B N D N Likely benign HGMD CM1614023: RMS (two
cases), germline, disease-causing
(30, 31). ClinVar RCV000654380.1:
DICER1 syndrome, VUS (32).






































VUS. COSMIC: Found in one case











not specified, likely benign.
RCV000301109.1: PPB, likely
benign
B, benign; D, damaging; DC, disease causing; Del, deleterious; MAF, minor allele frequency; N, neutral; n/a, not available; NP, not pathogenic; P, polymorphism; PD, possibly damaging; PPB, pleuropulmonary blastoma; RMS,
rhabdomyosarcoma; T, tolerated; VUS, variant of uncertain significance.
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FIGURE 2 | DICER1 protein comparison against different species and structure diagram of the protein. (A) Alignment of the DICER1 protein sequence across
species. Position of the identified amino acid variants is presented in bold characters. Most of the identified variants are well conserved across species. (B) Scheme of
the structure of the DICER1 protein and localization of studied variants. The main functional domains of DICER1 are the helicase domain including DEXD/H (DEAD
box), TRBP-BD (trans-activation response RNA-binding protein-binding), HELICc (helicase conserved carboxy-terminal domain), and DUF283 (domain of unknown
function), followed by a platform domain which separates the PAZ (Piwi/Argonaute, Zwille) domain from the two distinct RNase III domains (RNase IIIa and RNase IIIb)
and the double-stranded RNA-binding domain (RBD). Localization of the DICER1 variants of interest described in this study is indicated by an arrow. Aa, amino acid.
FIGURE 3 | Immunostaining for DICER1 in PitNETs and normal pituitary. Representative images are presented for Cases 1–6 (no slides were available for staining for
Case 7), as well as for a corticotropinoma from a patient with no DICER1 variants of interest and for a normal pituitary specimen. Magnification for all images: 20×.
variants were found in the gene region encoding the RNase
IIIb domain (end of exon 25–28). None of these seven patients
carried somatic hotspot USP8 mutations either. Interestingly,
the corticotropinoma found in case 2 (previously published as
PT282.03) displays somatic chromosomal instability, detected
by WES copy number variation analysis, as we have recently
reported (22).
DICER1 immunohistochemistry of the corticotropinomas
(Figure 3), revealed predominantly nuclear but also cytoplasmic
staining in most of the cells in Patients 1–3 and 5–6, in contrast
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with the purely cytoplasmic expression detected in PitNETs with
noDICER1 variants of interest and in the normal pituitary gland.
In contrast, tumor tissue from Patient 4 presented exclusively
cytoplasmic staining.
DISCUSSION
We hypothesized that DICER1 variants could play a role in
the development and function of corticotroph cells, as well
as in corticotroph tumorigenesis, based on the association of
DICER1 LOF with congenital CD due to PitB. Supporting this
hypothesis, we detected seven infrequent missense germline
DICER1 variants in an equal number of pediatric patients with
apparently sporadic corticotropinomas. In addition, we found an
overrepresentation of other more common DICER1 variants in
our cohort, compared with the general population. The study
of a unique large cohort of young CD patients has allowed
us to identify such rare genetic alterations, which might very
infrequent in the general population of patients with PitNETs.
We confirmed variant transmission from one of the parents in
five of the cases of interest, but except for multinodular goiter in
Case 5, no familial or personal history of any of the components
of the DICER1 syndrome was found. There was, however, a
history of familial melanoma in DICER1 variant carrier relatives
of Case 1, and although not considered to be associated to
the syndrome, somatic DICER1 defects have been described in
melanoma cases. In the two cases where variant inheritance was
not proven, only one of the parents was available for testing; thus,
we could not determine whether those variants appeared de novo.
To date, the only pituitary lesion clearly associated with
DICER1 mutations is PitB, an infrequent undifferentiated and
aggressive subtype of PitNET first described by Scheithauer et al.
(7, 35). Twomain studies support this genetic association: a series
of 13 cases which confirmed DICER1 mutations in 11 patients
(nine proven germline), and a report of an infant with a germline
frameshift deletion and a somatic missense variant causing
aggressive CD (8, 9). In a recent report, a DICER1 mutation
carrier was diagnosed with a microprolactinoma and papillary
thyroid cancer with multinodular goiter; she had a daughter who
died of ovarian cancer (36). Although the occurrence of a PitNET
in this patient could be a coincidence, an association with the
DICER1 defect cannot be ruled out.
All the variants identified in our patients have been classified
previously as benign, likely benign, or VUS regarding their
association with the DICER1 syndrome and other reported
phenotypes, but no experimental data were found in the literature
to validate their functional effects. They could potentially affect
the tumor suppressor function of DICER1, although they are
not clustered together in a specific protein domain (Figure 2).
Performing the functional experiments required to analyze the
impact of these variants was, however, beyond the scope of this
manuscript. Causality has not been proven between DICER1
loss-of-function and PitNETs other than PitB, and our patients
present a phenotype quite distinct from the DICER1 syndrome.
Therefore, although non-syndromic corticotropinomas could be
a new DICER1-associated phenotype, at the moment we cannot
confidently determine whether the variants found in our patients
are indeed causative or if they could act as disease modifiers.
DICER1 variants causing the DICER1 syndrome usually result
in truncated proteins and are most often inherited, but appear de
novo in 10–20% of cases (37). Although the majority of patients
carry germline heterozygous variants, 10% of cases are due to
mosaic defects, and most patients harbor second hits (somatic
variants or, less frequently, LOH) (38). While germline variants
can affect any region of the protein, reported somatic variants
are localized in hotspots within the RNase IIIb domain and
lead to reduced processing of mature 5
′
miRNA strands, shifting
the mature miRNA expression toward 3
′
-derived miRNAs, a
potential oncogenic mechanism (39). In contrast, the variants
found in our patients are non-truncating and lie outside the
RNase IIIb domain, and no second hits were identified. Such
findings were not completely unexpected, given the relatively
benign phenotype of the tumors (none of the patients presented
with pituitary blastoma or neonatal disease), and could indicate
the presence of alternative causative genetic defects, meaning that
DICER1 variants could be merely contributory in this setting.
Interestingly, none of these CD cases harbored somatic USP8
mutations, which are rather frequent among sporadic CD cases,
including in our cohort (17).
Another important observation from our study is
the preferential nuclear localization of DICER1 by
immunohistochemistry. Under physiological conditions,
most of the functions of the DICER1 protein take place in
the cytoplasm, but a small amount of the protein localizes
to the nucleus, where it takes part in non-canonical RNAi
processing, and DNA damage triggers its nuclear accumulation
(40, 41). Therefore, the staining pattern observed could indicate
either a response to previously induced DNA damage or an
abnormal subcellular localization of defective DICER1 proteins.
Unfortunately, inconsistencies in antibody performance for
DICER1 immunohistochemistry have been reported in the
literature (42). Analyzing a larger collection of tumors would
be required to determine whether such findings are either
indicative of DICER1 alterations, or a display of a physiological
cellular response to tumorigenic stimuli. Of note, two patients
had a histopathological diagnosis of Crooke’s cell adenoma.
Little is known about the molecular mechanisms underlying
this relatively rare and particularly aggressive subtype of
corticotropinoma, which represents 5.9% of the cases (n = 10)
in our pediatric cohort (43). Whether DICER1 defects could be
linked to this phenotype requires further investigations.
In conclusion, the identification of seven pediatric patients
with corticotropinomas harboring heterozygous DICER1
variants revealed a possible role for DICER1 gene defects in
corticotroph tumorigenesis. Further studies are required to assess
the functional effect of these variants on miRNA processing,
as well as to explain the specific role of DICER1 in the normal
pituitary gland and in corticotroph tumorigenesis.
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